Ahead of ad­comm, FDA dis­cuss­es Seik­a­gaku's mixed tri­al re­sults for its lum­bar disc her­ni­a­tion in­jec­tion

Japan-based Seik­a­gaku will face an FDA ad­vi­so­ry com­mit­tee on Fri­day, with the agency rais­ing con­cerns ahead of the meet­ing re­gard­ing the ef­fi­ca­cy of its con­do­liase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER